Reata announces patient enrollment in clinal trial of Bardoxolone Methyl
Category: #healthcare  By Akshay Kedari  Date: 2019-06-01
  • share
  • Twitter
  • Facebook
  • LinkedIn

Reata announces patient enrollment in clinal trial of Bardoxolone Methyl

Reata Pharmaceuticals, a clinical-stage biopharmaceutical company recently announced enrollment of first patient in the Phase 3 FALCON trial of bardoxolone in patients with ADPKD (autosomal dominant polycystic kidney disease), cites source.

For the record, Bardoxolone is an experimental oral activator of NrF2, that induces molecular pathways to restore mitochondrial functioning, inhibiting pro-inflammatory signaling & reducing oxidative stress. The drug has been granted orphan drug designation to treat pulmonary arterial hypertension & Alport syndrome by FDA.

Warren Huff, Reata’s Chief Executive Officer & President was reportedly quoted saying that autosomal dominant polycystic kidney disease is a commonly inherited form of chronic kidney disease.  Even with standard treatment, by 60 years of age, approximately 50% of the ADPKD patients will progress to end-stage kidney disease.

Huff added that significant improvements have been observed in kidney functions in the Phase 2 PHOENIX study of ADPKD cohort. Historically, strong correlations are observed between eGFR after 12 weeks of Bardoxolone Methyl treatment & 1 year retained eGFR benefits in other forms of chronic kidney diseases. Bardoxolone Methyl is expected to serve as a meaningful treatment option for patients with autosomal dominant polycystic kidney disease.

FALCON is an international trial that is studying efficiency & safety of Bardoxolone Methyl in 300 patients with autosomal dominant polycystic kidney disease, randomized evenly to active or placebo drug. The trial is expected to enroll a broad range of patients of age 18-70 years, with an estimated eGFR (estimated glomerular filtration rate) between 30-90 ml/min/1.73 m2. 

The chief efficacy endpoint for FALCON is change from baseline estimated glomerular filtration rate compared to placebo after 48 weeks of treatment, which is followed by a 4-week drug withdrawal period, also known as retained eGFR benefit. Based upon guidance from USFDA, an analysis of retained eGFR indicating an improvement than placebo after 1 year of bardoxolone treatment might aid approval. Also, an improvement than placebo after 2 years of treatment, might aid full approval.

Source credits : https://www.globenewswire.com/news-release/2019/05/30/1859256/0/en/Reata-Announces-First-Patient-Enrolled-in-Phase-3-FALCON-Trial-of-Bardoxolone-Methyl-for-the-Treatment-of-Autosomal-Dominant-Polycystic-Kidney-Disease.html

About Author

Akshay Kedari    

Akshay Kedari

Akshay holds a Bachelor’s degree in computer engineering. Despite having a penchant for software development and the like, Akshay took to writing as a career owing to his passion for the field. Presently, Akshay writes articles for itresearchbrief.com and a few oth...

Read More>>

More News By Akshay Kedari

Junshi Biosciences completes enrollment for Phase I COVID-19 study
Junshi Biosciences completes enrollment for Phase I COVID-19 study
By Akshay Kedari

  JS016 is apparently unique to the SARS-CoV-2 surface spike protein receptor-binding domain...

Hinterland Metals inks letter of intent to procure Novamind Ventures
Hinterland Metals inks letter of intent to procure Novamind Ventures
By Akshay Kedari

Hinterland Metals Inc., a junior mineral exploration firm based in Canada, has reportedly announced ...

Walmart to turn parking lots into drive-in theaters with Tribeca
Walmart to turn parking lots into drive-in theaters with Tribeca
By Akshay Kedari

American retail giant, Walmart Inc. has recently announced that it will be collaborating with Tribec...